INT149263

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2005
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 4
Total Number 5
Disease Relevance 1.00
Pain Relevance 2.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP3A4) oxidoreductase activity (CYP3A4) endoplasmic reticulum (CYP3A4)
enzyme binding (CYP3A4) lipid metabolic process (CYP3A4) cytoplasm (CYP3A4)
CYP3A4 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 10 96.08 Very High Very High Very High
Buprenorphine 58 94.64 High High
methadone 91 92.24 High High
withdrawal 30 88.52 High High
Versed 15 88.32 High High
Inflammation 19 85.96 High High
opiate 7 77.76 Quite High
agonist 14 74.68 Quite High
Paracetamol 4 69.60 Quite High
cytokine 4 65.28 Quite High
Disease Link Frequency Relevance Heat
Disease 16 98.80 Very High Very High Very High
Necrosis 1 98.68 Very High Very High Very High
Cancer 18 98.32 Very High Very High Very High
Substance Withdrawal Syndrome 15 88.88 High High
INFLAMMATION 14 85.96 High High
Injury 2 81.64 Quite High
Toxicity 56 70.24 Quite High
Opiate Addiction 12 63.28 Quite High
Aging 2 60.08 Quite High
Infection 3 48.96 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The effect of itraconazole, a potent inhibitor of the CYP3A isoenzyme family, on the pharmacokinetics of imidafenacin, a novel synthetic muscarinic receptor antagonist, was investigated.
Spec (investigated) Regulation (effect) of Negative_regulation (inhibitor) of CYP3A associated with antagonist
1) Confidence 0.44 Published 2008 Journal J Clin Pharmacol Section Abstract Doc Link 18218784 Disease Relevance 0 Pain Relevance 0.05
In contrast, for many PIs these drug interactions are opposite to their inhibition of CYP3A4 and thus most likely due to other mechanisms.


Regulation (opposite) of Negative_regulation (inhibition) of CYP3A4
2) Confidence 0.42 Published 2010 Journal Curr HIV/AIDS Rep Section Body Doc Link PMC2892618 Disease Relevance 0.23 Pain Relevance 1.47
The impact of inactivation of intestinal wall CYP3A depends on the values of the inactivation parameters, the residence time of the inhibitor at the site of CYP3A, and the relative contribution of intestinal and hepatic metabolism to the first-pass metabolism of a given drug.
Regulation (depends) of Negative_regulation (inactivation) of CYP3A
3) Confidence 0.27 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661603 Disease Relevance 0.06 Pain Relevance 0.12
The interindividual variations in enzyme activity, polypharmacy, diseases, and genetic factors are all potentially important factors affecting the outcomes of mechanism-based inactivation of CYP3A4.
Regulation (affecting) of Negative_regulation (inactivation) of CYP3A4 associated with disease
4) Confidence 0.27 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661603 Disease Relevance 0.31 Pain Relevance 0.22
plays a pivotal role in the suppression of CYP3A4 through interactions of NF-?
Regulation (role) of Negative_regulation (suppression) of CYP3A4
5) Confidence 0.15 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.40 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox